Original from: Danaher
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted.
Key Third Quarter 2024 Results
Net earnings were $818 million, or $1.12 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.71.
Revenues increased 3.0% year-over-year to $5.8 billion and non-GAAP core revenue increased 0.5%.
Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.2 billion.
Rainer M. Blair, President and Chief Executive Officer, stated, "Our team delivered strong third quarter results, including better-than-expected revenue growth. We were especially pleased with the continued positive momentum in our bioprocessing business and believe Cepheid gained market share in molecular testing again this quarter."
Blair continued, "Looking ahead, we believe the combination of our leading portfolio and DBS-driven execution differentiates Danaher and provides a strong foundation for sustainable long-term value creation while helping to meaningfully improve human health."
Fourth Quarter and Full Year 2024 Outlook
The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines.
For the fourth quarter 2024, the Company anticipates that non-GAAP core revenue will decline low-single digits year-over-year. For full year 2024, the Company continues to expect that non-GAAP core revenue will be down low-single digits year-over-year.
